<DOC>
	<DOCNO>NCT02240316</DOCNO>
	<brief_summary>This observational study aim assess therapeutic responsiveness MabThera SC patient malignant lymphomas everyday clinical practice condition . Patients previously untreated CD-20 positive follicular non-Hodgkin 's lymphoma ( NHL ) previously untreated CD-20 positive diffuse large B-cell lymphoma ( DLBCL ) plan therapy MabThera SC accord assessment physician prospectively enrolled observation . No study specific measure require ; treatment documentation perform accord usual clinical practice .</brief_summary>
	<brief_title>An Observational Study Patients With Malignant Lymphomas Treated With MabTheraÂ® SC Everyday Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Women men age &gt; =18 year Previously untreated CD20 positive follicular NHL Previously untreated CD20 positive DLBCL Planned therapy MabThera SC accord assessment physician ( start independent study ) Suitability therapy MabThera SC All contraindication , interaction incompatibility therapy MabThera SC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>